Published in Invest New Drugs on October 01, 2005
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer (2010) 1.87
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Letter: Creatinine clearance: bedside estimate. Ann Intern Med (1973) 2.52
Chemotherapy for malignant gliomas. J Neurosurg (1988) 1.49
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol (2003) 1.15
Recurrent malignant glioma in adults. Curr Treat Options Oncol (2002) 1.11
Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol (1991) 1.10
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol (1995) 1.09
Chemotherapy for high-grade gliomas. Br J Cancer (2000) 1.09
Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol (1989) 1.07
Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin Cancer Res (1995) 1.05
Temozolomide in the treatment of recurrent malignant glioma. Cancer (2004) 1.04
A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol (1994) 1.04
Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res (1987) 1.03
Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res (1998) 1.00
The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest (1996) 0.92
The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest (1990) 0.91
Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol (1991) 0.87
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin Cancer Res (1997) 0.83
Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Biochem Pharmacol (1996) 0.82
Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother Pharmacol (1990) 0.80
Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res (2003) 0.79
Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems. Cancer Res (1990) 0.77
The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res (2004) 0.76
A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs (2002) 0.75
A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. Clin Cancer Res (2002) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med (2009) 5.50
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol (2012) 4.27
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology (2007) 3.85
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol (2006) 3.83
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res (2006) 3.83
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol (2003) 3.18
Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology (2007) 3.08
Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol (2009) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol (2009) 2.84
Malignant primary cardiac tumors: review of a single institution experience. Cancer (2008) 2.59
Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol (2004) 2.53
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol (2014) 2.42
Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol (2006) 2.41
Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology (2009) 2.37
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. J Clin Oncol (2009) 2.32
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol (2005) 2.28
Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg (2012) 2.22
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20
A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol (2002) 2.18
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol (2010) 2.06
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
'Spindle cell oncocytoma' of the adenohypophysis: a tumor of folliculostellate cells? Am J Surg Pathol (2002) 1.98
Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest (2002) 1.86
Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol (2004) 1.85
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2010) 1.83
Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. J Pain Symptom Manage (2007) 1.83
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol (2003) 1.76
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res (2006) 1.75
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 1.75
An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol (2009) 1.73
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet (2012) 1.73
Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67
Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol (2007) 1.66
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
Treatment of pituitary neoplasms with temozolomide: a review. Cancer (2010) 1.63
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood (2007) 1.63
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res (2007) 1.61
Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila) (2011) 1.57
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2002) 1.55
Fibromatosis: a potential sequela of neuromuscular choristoma. J Neurosurg (2011) 1.55
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol (2003) 1.54
Microglia in brain tumors. Glia (2002) 1.54
Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One (2011) 1.53
Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res (2013) 1.53
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res (2006) 1.51
Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol (2006) 1.50
Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol (2006) 1.50
PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol (2010) 1.47
The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol (2007) 1.47
18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports. Leuk Lymphoma (2010) 1.47
Hemangioblastoma of spinal nerve: a report of six cases. Clin Neuropathol (2013) 1.45
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2011) 1.45
Global democratic consensus on neuropathological disease criteria. Lancet Neurol (2002) 1.44
Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol (2006) 1.43
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol (2013) 1.42
Angiomyxofibromatous tumor of the falx cerebri. Am J Surg Pathol (2006) 1.40
Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res (2011) 1.40
Plexiform schwannoma: a clinicopathologic overview with emphasis on the head and neck region. Hum Pathol (2008) 1.40
Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol (2006) 1.39
Degradation of a cytosolic protein requires endoplasmic reticulum-associated degradation machinery. J Biol Chem (2008) 1.39
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol (2009) 1.38
Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg (2008) 1.37
Spinal cord gliomas: A multi-institutional retrospective analysis. Int J Radiat Oncol Biol Phys (2005) 1.37
The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest (2013) 1.37
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res (2008) 1.36
Spinal meningiomas in patients younger than 50 years of age: a 21-year experience. J Neurosurg (2003) 1.35
Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res (2014) 1.35
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33